Search results
Author(s):
John GF Cleland
Added:
9 months ago
ESC-HFA 23 - Prof John Cleland (University of Glasgow, UK) joins us onsite to discuss the IRONMAN trial (NCT02642562).
IRONMAN was a randomised, open-label multicenter trial, which aimed to assess the effectiveness of intravenous iron in patients with heart failure and iron deficiency as compared to standard care. It demonstrated that the administration of IV FDI was associated with lower rates…
View more
Author(s):
Javed Butler
Added:
2 years ago
In this short interview, Dr Javed Butler (University of Mississippi Medical Center, Jackson, MS, US) discusses the findings of an analysis from the EMPEROR Preserved trial. In EMPEROR-Preserved, empagliflozin treatment was associated with reduction in the risk of the primary endpoint of CV death or HF hospitalization in patients with HFpEF. In this analysis, presented at AHA 2021, the…
View more
ACC 23: The BMAD Trial
Author(s):
John Boehmer
Added:
1 year ago
Video
Author(s):
Stefan Anker
,
Harriette Van Spall
Added:
2 years ago
Late-breaker host, Dr Harriette Van Spall (McMaster University, CA)is joined by Principal Investigator, Prof Stefan Anker (Charite Campus Virchow Clinic, DE) for an in-depth discussion on the latest data from the EMPEROR-Preserved trial presented at ESC Congress 2021.
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction evaluated the effects of…
View more
Early Initiation of Tolvaptan is Associated with Early Discharge in Elderly Heart Failure Patients
Author(s):
Shunsuke Kiuchi
,
Shinji Hisatake
,
Yoshiki Murakami
,
et al
Added:
2 years ago
Article
The ISCHEMIA Trial: Editorial
Author(s):
Pablo Avanzas
,
Juan Carlos Kaski
Added:
2 years ago
Article
Author(s):
Markus Flesch
Added:
3 years ago
Introduction
Chronic heart failure (HF) is a common, malignant disease and is a major economic burden for healthcare systems in developed nations. It affects 5% to 10% of all people. In Germany, approximately 150,000 people are newly diagnosed with HF per year. Fifteen per cent of approximately 1.6 million HF patients in Germany are in advanced HF status, being classified as stage III-IV…
View more
Author(s):
Martin R Cowie
Added:
3 years ago
Introduction
Management of heart failure consumes 1% to 2% of the healthcare budget in developed countries, with the largest share due to the cost of hospitalisations.1 A pan-European survey has shown that up to 65% of patients hospitalised with heart failure have a past history of chronic heart failure.2 Such admissions are usually long, with an average duration of 11 days. In-hospital…
View more
Author(s):
Martin R Cowie
Added:
3 years ago
Management of heart failure consumes 1% to 2% of the healthcare budget in developed countries, with the largest share due to the cost of hospitalisations.1 A pan-European survey has shown that up to 65% of patients hospitalised with heart failure have a past history of chronic heart failure.2 Such admissions are usually long, with an average duration of 11 days. In-hospital mortality was reported…
View more
Author(s):
Kashish Goel
,
Colin M Barker
,
JoAnn Lindenfeld
Added:
3 years ago
Heart failure (HF) is a growing epidemic, with an estimated 6.2 million adults (≥20 years) affected between 2013 and 2016 in the US.1 The prevalence is increasing and is expected to reach 8 million by 2030.1 Mitral regurgitation (MR) is common in HF patients, especially in those with ischaemia, left ventricular (LV) dysfunction or dilated cardiomyopathy. MR in the absence of structural…
View more